poisar

Stocks · News reference

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Jul 31, 2026, 5:48 AMTanya Rawat

Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MYGN
Source
benzinga
Observed
Jul 31, 2026, 5:48 AM
Checked
Jul 31, 2026, 5:47 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 7, 2026, 6:54 PMBragar Eagel & Squire, P.C.

    MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

    Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.

    Read original at globenewswire-inc
    MYGN